Amendment: SEC Form SC 13G/A filed by bluebird bio Inc.
$BLUE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/18/2024 | Neutral → Underweight | Analyst | |
| 11/15/2024 | Neutral → Underweight | JP Morgan | |
| 11/15/2024 | $3.00 → $0.50 | Buy → Neutral | BofA Securities |
| 8/15/2024 | Overweight → Neutral | JP Morgan | |
| 12/11/2023 | Hold → Reduce | HSBC Securities | |
| 12/8/2023 | $3.00 → $7.00 | Underweight → Equal-Weight | Morgan Stanley |
| 10/17/2023 | Neutral | Cantor Fitzgerald | |
| 9/6/2023 | $4.21 | Buy | HSBC Securities |
On March 26, 2024, bluebird announced that it will restate its consolidated financial statements for the first three quarters and full-year 2022, as well as the first three quarters of 2023. As a result, the Company's Annual Report Form 10-K for 2023 and its Q1 2024 Form 10-Q have been delayed. Consistent with previous updates, the restatement is not expected to impact the Company's cash position or revenue. Sterling will transition to oversee the restatement process upon his start date.
Sterling most recently served as chief financial officer of Renalytix plc, a diagnostics company focused on clinical management of kidney disease.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. Below are some instances of options activity happening in the Health Care sector: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume MRNA PUT SWEEP BULLISH 05/17/24 $122.00 $36.6K 148 2.3K ALNY PUT SWEEP BEARISH 07/19/
Analyst downgraded Bluebirdbio from Neutral to Underweight
JP Morgan downgraded Bluebirdbio from Neutral to Underweight
BofA Securities downgraded Bluebirdbio from Buy to Neutral and set a new price target of $0.50 from $3.00 previously
DEFA14A - bluebird bio, Inc. (0001293971) (Filer)
S-8 - bluebird bio, Inc. (0001293971) (Filer)
10-Q - bluebird bio, Inc. (0001293971) (Filer)
4 - bluebird bio, Inc. (0001293971) (Issuer)
4 - bluebird bio, Inc. (0001293971) (Issuer)
4 - bluebird bio, Inc. (0001293971) (Issuer)
For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali
For Immediate Release: August 17, 2022 Today, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions. “Today’s approval is an important advance in the treatment of beta-thalassemia, particularly in individuals who require ongoing
- 74 patient starts completed or scheduled to date in 2024 across bluebird's commercial portfolio - - Third quarter 2024 net revenue of $10.6 million reflects quarter-to-quarter fluctuations in drug product infusions; anticipate at least $25 million of net revenue in the fourth quarter - - Management to host conference call today, November 14, 2024 at 8:00 am ET - bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September 30, 2024, including recent commercial and operational progress. "Patient starts more than doubled from our second to third quarter update, providing clear evidence
bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird bio" or the "Company") today announced that it partially adjourned its annual meeting of stockholders ("Annual Meeting") on Wednesday, November 6, 2024, to allow the Company to solicit additional votes to obtain approval of Proposal 4, a reverse stock split, as described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on September 26, 2024 (the "proxy statement"). The Company's stockholders approved Proposals 1, 2, 5, 6 and 7, and did not approve Proposal 3 during the Annual Meeting held earlier today (all proposals as described in the proxy statement). The Annual Meeting will reconvene on December 4,
Actions intended to reduce cash operating expenses by approximately 20% Management team to host conference call today, September 24 at 8:00 am ET Following a comprehensive review of its operations, bluebird bio, Inc. (NASDAQ:BLUE) today announced that the Company is implementing a restructuring intended to optimize the Company's cost structure and enable quarterly cash flow break-even in the second half of 2025. The restructuring is expected to result in a 20% reduction in cash operating expenses when fully realized in Q3 2025, compared to the prior reporting period. The initiative includes a reduction in the Company's workforce of approximately 25%. The Company's cash flow break-even tar
- 74 patient starts completed or scheduled to date in 2024 across bluebird's commercial portfolio - - Third quarter 2024 net revenue of $10.6 million reflects quarter-to-quarter fluctuations in drug product infusions; anticipate at least $25 million of net revenue in the fourth quarter - - Management to host conference call today, November 14, 2024 at 8:00 am ET - bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September 30, 2024, including recent commercial and operational progress. "Patient starts more than doubled from our second to third quarter update, providing clear evidence
bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird bio" or the "Company") today announced that it partially adjourned its annual meeting of stockholders ("Annual Meeting") on Wednesday, November 6, 2024, to allow the Company to solicit additional votes to obtain approval of Proposal 4, a reverse stock split, as described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on September 26, 2024 (the "proxy statement"). The Company's stockholders approved Proposals 1, 2, 5, 6 and 7, and did not approve Proposal 3 during the Annual Meeting held earlier today (all proposals as described in the proxy statement). The Annual Meeting will reconvene on December 4,
bluebird bio, Inc. (NASDAQ:BLUE) today announced that new and updated data from its lentiviral vector (LVV) gene addition programs in patients with sickle cell disease who have a history of vaso-occlusive events and patients with beta-thalassemia who require regular blood transfusions will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. The meeting will take place December 7-10, 2024 at the San Diego Convention Center and online. "The data to be presented at ASH 2024 continue to underscore the transformative, long-term potential of bluebird's gene therapies," said Richard Colvin, M.D., Ph.D., chief medical officer, bluebird bio. "Our programs co
SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)
SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)
SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)
CHICAGO, June 2, 2024 /PRNewswire/ -- 2Flo Ventures, an emerging venture capital firm and startup studio focused on the discovery, development, and commercialization of healthcare solutions that address disparities in outcomes and health equity broadly, is pleased to announce the addition of Dr. Charlotte Jones-Burton as a Partner and Head of Life Science Product Development and Strategy. 2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a PartnerDr. Jones-Burton brings to 2Flo Ventures nearly two decades of experience in th
bluebird bio, Inc. (NASDAQ:BLUE) today announced that O. James Sterling, has been appointed chief financial officer (CFO), effective June 10, 2024. Mr. Sterling most recently served as chief financial officer of Renalytix plc, a diagnostics company focused on clinical management of kidney disease. "We are thrilled to welcome James to bluebird bio. We are confident that his extensive experience in the healthcare sector and knowledge of the capital markets will position us well as we work to prove the commercial gene therapy model, and demonstrate progress on our path to profitability," said Andrew Obenshain, chief executive officer, bluebird bio. "It is an honor to be joining bluebird bi
Believes 2seventy Could Be Conservatively Worth ~$9 Per Share if the Company Exclusively Focuses on Its Most-Valuable Asset Abecma, Reduces Corporate Overhead and Makes Improvements to the Composition of the Management Team and Board Engine Capital LP, which owns approximately 3% of 2seventy bio, Inc.'s (NASDAQ:TSVT) ("2seventy" or the "Company") outstanding shares, today announced that it sent the below letter the Company's Board of Directors (the "Board"). *** December 6, 2023 2seventy bio, Inc. 60 Binney Street Cambridge, MA 02142 Attention: Board of Directors Dear Members of the Board: Engine Capital LP (together with its affiliates, "Engine" or "we"), is a meaningful shareh